The results of the use of etravirine within 48 weeks in patients in Saint-Petersburg in real clinical practice

Abstract

The aim of the work was to evaluate the efficacy, safety and tolerability of etravirine-containing regimens in patients with treatment experience in real clinical practice.Materials and methods. A retrospective analysis of 300 outpatient records of HIV-infected patients with treatment experience, which were converted to regimens containing etravirine (ETR) as the third component, was performed. The reasons for switching to ETR-containing regimens were adverse events, comorbidities, and virological failure. The main criterion for the effectiveness of the scheme was the proportion of patients with an undetectable level of viral load at 48 weeks of treatment. Additional criteria for evaluating the effectiveness and safety of the scheme were the dynamics of the number of CD4-lymphocytes, the frequency and nature of adverse reactions.Results. The proportion of patients with virologic suppression less than 50 kop/mL was 83% versus 77,3% at the time of switching (p<0.005). The percentage of patients with CD4-lymphocytes level >500 ctlls/um increased from 40,3% to 58%, and the percentage of patients with CD4 level <200 cells/um decrease more than twice from 13% to 6% (p<0.005). The mean level os ALT decreased significantly from 47,52±66,45 units/L to 42,65±55,18 units/L (p=0,019). The average level of total cholesterol decreased by 8.7% from 5,64±1,37 mmol/L to 5.15±0.98 mmol/L (p<0,001). The average BMI after switching to ETR did not change and amounted to 24,07±4,07, 24,2±4,05, respectively (p=0,347).Conclusions. The results of this study confirm that etravirine is well tolerated and may be an option for patients who have HIV RNA suppression on ART but develop adverse reactions, and may also be part of a second-line ART regimen in patients who fail first-line regimen.

Keywords

• hiv infection
• etravirine
• virological and immunological efficacy
• metabolic disorders